The chief executive of Indivior, the FTSE 250 addiction specialist, flew into London last week for a brief visit, including to catch up with employees at the group’s UK office in Slough.
Staff at the mid-cap pharmaceuticals company should have had cause for encouragement from Mark Crossley, the American former finance chief, after more than five years of uncertainty for the workforce and investors on both sides of the Atlantic.
Indivior has been beset by costly patent litigation as well as the fallout from a US regulatory investigation into the marketing of Suboxone Film, its bestselling anti-opioid treatment.
Finally, though, Indivior is showing signs of turning a corner as it prepares to issue full-year results on February 22.
Indivior was spun off in 2014
